Objective: To compile a comprehensive summary of published human experience 2 with levodopa given intravenously, with a focus on information required by 3 regulatory agencies. 4
Introduction 25
Parkinson disease (PD), the second most common neurodegenerative disease, is associated with impairments in 26 dopaminergic neurotransmission in the basal ganglia. Replacement of dopamine has been the cornerstone of 27 treatment for PD. Because dopamine itself does not cross the blood-brain barrier (BBB), its immediate precursor 28 levodopa (L-3,4-dihydroxphenylalanine, L-DOPA) is adminstered since it does cross the BBB (Hornykiewicz, 29 1963; Cotzias et al., 1967; Birkmayer and Hornykiewicz, 2001) . Although purified levodopa was first ingested 30 by mouth in 1913 (Roe, 1997), it was first used for medical treatment by intravenous rather than oral 31 administration (Pare and Sandler, 1959; Birkmayer and Hornykiewicz, 2001) . 32
Oral levodopa has become the preferred method of treatment clinically, but intravenous levodopa 33 administration still holds advantages over the oral form for some research studies. First, the rapid administration 34 of intravenous levodopa is often necessary for certain study designs, including those focused on the 35 pharmacokinetics and pharmacodynamics of the drug. Additionally, intravenous administration leads to more 36 predictable plasma levodopa concentration because oral medications have highly variable absorption 37 characteristics, especially in PD patients (Bushmann et al., 1989) , with differences in absorption based on sex 38 and age (Robertson et al., 1989; Kompoliti et al., 2002) . Intravenous levodopa permits researchers to keep brain 39 levodopa concentrations constant while assessing physiological responses over time. Furthermore, intravenous 40 levodopa has sometimes been used clinically in patients who cannot tolerate oral medications, such as PD 41 patients during surgery or on total parenteral nutrition. 42 Current U.S. FDA regulations focus heightened scrutiny on research in which drugs are delivered by a route 43 for which the drug has not been approved. Predictably, in addition to any safety benefits, the heightened scrutiny 44 has also created practical obstacles to research with intravenous levodopa, as described for instance by Rascol 45 and colleagues (2001, p. 250) . Specifically, an IND (Investigational New Drug) application must be submitted if 46 risks of intravenous levodopa are significantly higher than those of oral levodopa ( §21 CFR 312.2(b)(iii)). 47 Therefore, the overall goal of this paper is to facilitate research use of IV levodopa by compiling a literature 48 Results 69 142 articles reporting intravenous levodopa administration were identified. Most subjects with parkinsonism 70 were diagnosed with idiopathic PD, but some studies reported a variety of etiologies including postencephalitic 71 and vascular parkinsonism and PSP. PD patients differed in their history of prior drug treatment before the 72 studies with conditions including de novo, fluctuating, on-off, and stable. Some subjects were treated with 73 levodopa for conditions other than PD (see Table 1 : Patient Populations and Response Parameters), including 74 other movement disorders (dystonia, progressive supranuclear palsy [PSP] , neuroleptic malignant syndrome 75
[NMS], primary psychiatric disorders (schizophrenia, mood disorders, personality disorders), endocrine 76 disorders (diabetes mellitus, essential obesity, hypopituitarism), hepatic disease (alcoholic cirrhosis, 77 steatohepatitis, hepatic encephalopathy), cardiac valvular disease, and asthma. Healthy controls were also 78 included in some studies. 79
Pharmacokinetic data were reported for a total of 251 human subjects (see Table 2 The pharmacodynamic data (see Table 3 : Reports of Human Experience with IV Levodopa) obtained from 87 the literature surveyed a total of 2651 human subjects, with a significant variety of patient groups studied and a 88 multitude of response parameters (see Table 1 ). From these articles, no side effects were reported for a total of 89 1260 subjects. The highest total dose was 4320 mg in one day, given to a patient with idiopathic PD and 90 carcinoma of the retina. The patient reported no side effects or adverse effects at this dose. The highest single 91 bolus dose was 200 mg, while the highest infusion rates were 5.0 mg/kg/hr. 92 the LD50 ranges from 450 mg/kg (administered intravenously) to 4449 mg/kg (administered subcutaneously). 138
Typical human doses are in the range of only 1 mg/kg; thus, human studies with intravenous levodopa 139 administer doses substantially lower than those dangerous to nonhuman mammals. 140
Intravenous levodopa has similar efficacy and side effects as oral levodopa (Connolly and Lang, 2014) and 141 dopamine agonists (Bonuccelli and Ceravolo, 2008) . These include GI (nausea, vomiting, and abdominal 142 discomfort) and neuropsychiatric effects (sedation, dyskinesias). Nausea and orthostatic hypotension, side 143 effects of both IV and oral levodopa, are largely blocked by PDIs and are less common in patients accustomed to 144 dopamimetic treatment. The other side effects are infrequent and neither serious nor life-threatening (Connolly 145 and Lang, 2014). When given with adequate PDI pretreatment, intravenous levodopa has minimal if any 146 cardiovascular effects (Siddiqi et al., in press). 147
The safety of IV levodopa is important for patients but also for regulatory review. Changing the route of 148 administration of any drug in a study traditionally necessitates submitting an IND application if changing the 149 route of administration "significantly increases the risks … associated with the use of the drug product" ( §21 150 CFR 312.2(b)(iii)). The data from our review of the literature suggest that intravenous administration of 151 levodopa does not significantly increase the associated risks of levodopa in comparison to oral administration. 152
In summary, studies conducted throughout the past half century support the safety of IV levodopa 153 administration in human patients. 154 No side effects mentioned. Levodopa was associated with increases in learning-related activation in the left dorsal premotor cortex and in the right pre-supplementary motor area. In the former region, there was recovery of the normal activation response by levodopa. In the latter region, there was a treatment-mediated gain of response in that significant learning-related activation was present only when the patients were scanned on levodopa therapy. None of the subjects suffered nausea or showed other signs of intolerance, or significant variations in blood pressure during the experiment. In diabetics and obese subjects, IV L-dopa causes a less marked HGH increase than in control subjects, with diabetics having more of an increase than obese subjects No nausea (except for one patient who was given oral levodopa); authors suggest that L-dopa undergoes decarboxylation and sulfation continuously even when administered intravenously.
Author contributions
(Henry et al., 1976) 13 Depression, otherwise healthy carbidopa none mentioned 50 mg (after a week's interval 6 pts got iv 50 mg DOPS or 100 mg L-DOPA without carbidopa) 50 mg/5 min No nausea, vomiting, hypertension, and "other untoward side effects".
The study was designed to "avoid such peripheral side effects by pretreating the patients with carbidopa." IV levodopa was associated with reduced learning compared with chronic oral treatment and placebo infusions. No significant changes were found in heart rate/rhythm or blood pressure between levodopa and placebo. ( In one case, a sudden improvement in a concomitant asthmatic stridor was observed. "Depression" and "physical symptoms" improved in patients who were classified as depressed but may have had PD as well.
(Ingvarsson, 1965b) 9 not given none mentioned none mentioned 50 mg iv 50 mg IV levodopa "abolishes asthmatic stridor."
(Jaffe et al., 1987) 6 PD carbidopa none mentioned ≥ 2 hours (at least 300 mg) 2.5 mg/min One subject had mild dyskinesia. Intravenous infusion of levodopa can affect the ERG in patients with PD, indicating that the human retina is sensitive to changes in the systemic levels of levodopa and that this drug or its metabolite cross the blood-retinal barrier.
(Juncos et al., 1987) 7 idiopathic PD carbidopa none mentioned 24 hr/day x 6-13 days ~1.5mg/kg /10 min (corrected for MW of L-Dopa instead of MW of L-Dopa methyl ester)
Motor fluctuations were markedly reduced with intravenous LDME. All patients noted an improvement in their condition during LDME treatment; reported benefits included improved sleep, attenuation of early morning akinesia or dystonia. There was no clinical or laboratory evidence of LDME toxicity. Effect on mood and anxiety was dose responsive. Six of 8 patients had mood response (increase in mood score greater than 20%) during high dose infusion. Reduction of anxiety began shortly after onset of high-dose infusion. Peak effect of anxiety occurred 30 minutes after infusion had been stopped and was followed by precipitous increase in anxiety. Patients had little insight into discrepancy between their subjective reports and how they appeared to observers during their dyskinetic and agitated, but relatively euphoric state.
(Maricle et al., 1998) 18 idiopathic PD none domperidone 2mg/kg daily x 2d 1 mg/kg/hr No significant side effects. Authors believe, "A significant mood response after a 2-day levodopa holiday supports the hypothesis that pharmacologic tolerance may be involved in this process and that sensitization may appear after a relatively brief period of abstinence form levodopa even in the first year of levodopa therapy."
(Marion et al., 1986) 3 PD benserazide none mentioned 755 -1750 mg / 12 hr 150mg / 10 min No significant side effects mentioned. The patients did not experience any major discomfort or inconvenience during the course of the infusions and were pleased with their improved motor performance. Infusion were given for 6 hrs on day 1, and 12 hrs on day 2. One patient had mild dyskinesia. The number of on-off switches decreased and the duration of "on" periods increased in all three patients during the infusion periods compared to oral therapy. Intravenous infusion of levodopa (with P.D.I.) can give reproducible periods of constant mobility in selected patients for up to 5 consecutive days. One patient felt a feeling of "euphoria" after initial infusion. Another patient had a symptomatic fall of blood pressure from 140/80 mm Hg to 70/30 mm Hg when rate was at 99 mg/h of levodopa, so the infusion rate was decreased to 60 mg/h. ( The same dose of L-Dopa produced progressively more severe dyskinesia with long-term L-dopa therapy but did not increase the duration of dyskinesia in patients. However increasing the dose of L-dopa in subjects with dyskinesia does not increase the severity of dyskinesia but does increase the duration of dyskinesia. Pulse and blood pressure fell, but to the same degree as with oral levodopa; "slight and transient" postural faintness (orthostasis); coldness of the limbs; nausea and vomiting; dyskinesias. No patient complained of palpitations during the infusions, and no arrhythmias were detected. Authors believe, "Continuous intravenous infusion of levodopa turns out to be the most effective way of abolishing the off state during a substantial period of the day."
(Rinne and Sonninen, 1968) 36
Idiopathic PD (24) and post-encephalitic PD (12) none none mentioned 1.5 mg/kg 1.5 mg/kg/10 min Pulse and blood pressure changes were comparable between levodopa and placebo. The patients were given constant intravenous L-dopa infusion for 12 hours x 3days. Mild somnolence, nausea, and occasional vomiting were the only side effects reported.. There was an increase in blood pressure (probably due to domperidone). Maximum optimal drug rate ranged from 30-104 mg/hr with mean 53.5 mg/hr. Mean PRA fell by 50%; significant increase in urinary sodium excretion and effective renal plasma flow; mean diastolic blood pressure fell with no reflex tachycardia. Mean diastolic pressure fell on infusion of L-dopa. Trends towards fall in mean systolic pressure and rise in mean pulse rate on infusion of L-dopa, but these were not significantly different from changes occurring on saline infusion.
(Zsigmond et al., 2012) 10 PD none none 281.25 mg 375 mg/hr for 45 minutes
No side effects mentioned. In 2 patients who had previously discontinued oral levodopa/carbidopa due to nausea, high doses of IV levodopa were well-tolerated and relieved symptoms. total references 142 Total 2776
